O	0	10	Randomised
O	11	16	phase
O	17	19	II
O	20	25	trial
O	26	36	evaluating
O	37	40	the
O	41	47	safety
O	48	50	of
B-intervention	51	63	peripherally
I-intervention	64	72	inserted
I-intervention	73	82	catheters
O	83	89	versus
B-control	90	99	implanted
I-control	100	104	port
I-control	105	114	catheters
O	115	121	during
O	122	130	adjuvant
O	131	143	chemotherapy
O	144	146	in
B-eligibility	147	155	patients
I-eligibility	156	160	with
I-eligibility	161	166	early
I-eligibility	167	173	breast
I-eligibility	174	180	cancer
O	180	181	.

O	182	186	Both
O	187	199	peripherally
O	200	208	inserted
O	209	216	central
O	217	226	catheters
O	227	228	(
O	228	233	PICCs
O	233	234	)
O	235	238	and
O	239	248	implanted
O	249	253	port
O	254	263	catheters
O	264	265	(
O	265	270	PORTs
O	270	271	)
O	272	275	are
O	276	280	used
O	281	284	for
O	285	293	adjuvant
O	294	306	chemotherapy
O	307	308	(
O	308	311	ACT
O	311	312	)
O	313	327	administration
O	328	330	in
O	331	339	patients
O	340	344	with
O	345	350	early
O	351	357	breast
O	358	364	cancer
O	365	366	(
O	366	369	EBC
O	369	370	)
O	370	371	.

O	372	374	We
O	375	380	aimed
O	381	383	to
O	384	391	compare
O	392	395	the
O	396	402	safety
O	403	410	between
O	411	416	PICCs
O	417	420	and
O	421	426	PORTs
O	427	429	in
O	430	434	this
O	435	442	setting
O	442	443	.

O	444	448	This
O	449	460	monocentric
O	461	466	phase
O	467	469	II
O	470	480	randomised
O	481	486	trial
O	487	488	(
O	488	499	NCT02095743
O	499	500	)
O	501	509	included
O	510	518	patients
O	519	523	with
O	524	527	EBC
O	528	531	who
O	532	536	were
O	537	545	eligible
O	546	549	for
O	550	553	ACT
O	553	554	.

O	555	563	Patients
O	564	568	with
O	569	577	curative
O	578	593	anticoagulation
O	594	601	therapy
O	602	606	were
O	607	615	excluded
O	615	616	.

O	617	620	The
O	621	628	primary
O	629	638	objective
O	639	642	was
O	643	645	to
B-outcome-Measure	646	654	identify
I-outcome-Measure	655	660	which
I-outcome-Measure	661	667	device
I-outcome-Measure	668	671	has
I-outcome-Measure	672	673	a
I-outcome-Measure	674	679	lower
I-outcome-Measure	680	691	probability
I-outcome-Measure	692	694	of
I-outcome-Measure	695	703	catheter
I-outcome-Measure	703	704	-
I-outcome-Measure	704	711	related
I-outcome-Measure	712	723	significant
I-outcome-Measure	724	731	adverse
I-outcome-Measure	732	738	events
I-outcome-Measure	739	740	(
I-outcome-Measure	740	742	CR
I-outcome-Measure	742	743	-
I-outcome-Measure	743	747	SAEs
I-outcome-Measure	747	748	)
I-outcome-Measure	749	755	within
I-outcome-Measure	756	759	the
I-outcome-Measure	760	762	35
I-outcome-Measure	763	768	weeks
I-outcome-Measure	769	774	after
I-outcome-Measure	775	781	device
I-outcome-Measure	782	794	implantation
O	794	795	.

O	796	799	The
O	800	809	secondary
O	810	819	objective
O	820	823	was
O	824	826	to
O	827	835	evaluate
B-outcome-Measure	836	843	quality
I-outcome-Measure	844	846	of
I-outcome-Measure	847	851	life
I-outcome-Measure	852	853	(
I-outcome-Measure	853	856	QoL
I-outcome-Measure	856	857	)
O	858	861	and
B-outcome-Measure	862	869	patient
I-outcome-Measure	870	882	satisfaction
O	882	883	.

O	884	888	From
O	889	897	February
O	898	902	2014
O	903	905	to
O	906	909	May
O	910	914	2018
O	914	915	,
B-total-participants	916	919	256
O	920	928	patients
O	929	933	were
O	934	942	included
O	942	943	,
O	944	947	and
B-total-participants	948	951	253
O	952	953	(
O	953	955	99
O	955	956	%
O	956	957	)
O	958	962	were
O	963	971	analysed
O	971	972	.

O	973	980	Overall
O	980	981	,
O	982	984	31
O	985	993	patients
O	994	995	(
O	995	997	12
O	997	998	.
O	998	999	2
O	999	1000	%
O	1000	1001	)
O	1002	1013	experienced
B-outcome	1014	1016	CR
I-outcome	1016	1017	-
I-outcome	1017	1021	SAEs
O	1021	1022	,
O	1023	1028	which
O	1029	1035	mainly
O	1036	1044	included
O	1045	1059	thromboembolic
O	1060	1066	events
O	1066	1067	.

O	1068	1070	In
O	1071	1073	an
O	1074	1083	intention
O	1083	1084	-
O	1084	1086	to
O	1086	1087	-
O	1087	1092	treat
O	1093	1101	analysis
O	1101	1102	,
O	1103	1106	the
B-outcome	1107	1118	probability
I-outcome	1119	1123	that
I-outcome	1124	1125	a
I-outcome	1126	1128	CR
I-outcome	1128	1129	-
I-outcome	1129	1132	SAE
I-outcome	1133	1138	would
I-outcome	1139	1144	occur
O	1145	1148	was
B-iv-bin-percent	1149	1150	7
I-iv-bin-percent	1150	1151	.
I-iv-bin-percent	1151	1152	8
I-iv-bin-percent	1152	1153	%
O	1154	1155	(
B-iv-bin-abs	1155	1157	10
O	1158	1164	events
O	1164	1165	)
O	1166	1170	with
O	1171	1176	PORTs
O	1177	1183	versus
B-cv-bin-percent	1184	1186	16
I-cv-bin-percent	1186	1187	.
I-cv-bin-percent	1187	1188	6
I-cv-bin-percent	1188	1189	%
O	1190	1191	(
B-cv-bin-abs	1191	1193	21
O	1194	1200	events
O	1200	1201	)
O	1202	1206	with
O	1207	1212	PICCs
O	1213	1214	(
O	1214	1220	hazard
O	1221	1226	ratio
O	1227	1228	[
O	1228	1230	HR
O	1230	1231	]
O	1232	1233	=
O	1234	1235	2
O	1235	1236	.
O	1236	1237	2
O	1238	1239	[
O	1239	1240	1
O	1240	1241	.
O	1241	1243	03
O	1243	1244	-
O	1244	1245	4
O	1245	1246	.
O	1246	1248	62
O	1248	1249	]
O	1249	1250	,
O	1251	1252	P
O	1253	1254	=
O	1255	1256	0
O	1256	1257	.
O	1257	1260	036
O	1260	1261	)
O	1261	1262	.

O	1263	1265	In
O	1266	1267	a
O	1268	1271	per
O	1271	1272	-
O	1272	1280	protocol
O	1281	1289	analysis
O	1289	1290	,
O	1291	1296	PICCs
O	1297	1301	were
O	1302	1306	also
O	1307	1317	associated
O	1318	1322	with
O	1323	1324	a
O	1325	1331	higher
B-outcome	1332	1336	risk
I-outcome	1337	1339	of
I-outcome	1340	1342	CR
I-outcome	1342	1343	-
I-outcome	1343	1347	SAEs
O	1348	1352	than
O	1353	1358	PORTs
O	1359	1360	(
O	1360	1362	HR
O	1363	1364	=
O	1365	1366	2
O	1366	1367	.
O	1367	1369	82
O	1370	1371	[
O	1371	1372	1
O	1372	1373	.
O	1373	1375	26
O	1375	1376	-
O	1376	1377	6
O	1377	1378	.
O	1378	1380	25
O	1380	1381	]
O	1381	1382	,
O	1383	1384	P
O	1385	1386	=
O	1387	1388	0
O	1388	1389	.
O	1389	1392	007
O	1392	1393	)
O	1393	1394	.

O	1395	1404	Regarding
O	1405	1408	the
O	1409	1418	secondary
O	1419	1429	objectives
O	1429	1430	,
O	1431	1433	if
O	1434	1439	there
O	1440	1443	was
O	1444	1446	no
O	1447	1457	difference
O	1458	1460	in
B-outcome	1461	1464	QoL
O	1465	1472	between
O	1473	1476	the
O	1477	1481	arms
O	1481	1482	,
O	1483	1487	then
O	1488	1501	significantly
O	1502	1506	more
B-outcome	1507	1517	discomfort
O	1518	1521	was
O	1522	1530	reported
O	1531	1536	among
O	1537	1545	patients
O	1546	1550	with
O	1551	1556	PICCs
O	1557	1561	than
O	1562	1567	among
O	1568	1576	patients
O	1577	1581	with
O	1582	1587	PORTs
O	1588	1589	(
O	1589	1590	P
O	1591	1592	=
O	1593	1594	0
O	1594	1595	.
O	1595	1598	002
O	1599	1604	after
O	1605	1617	implantation
O	1618	1621	and
O	1622	1623	P
O	1624	1625	<
O	1626	1627	0
O	1627	1628	.
O	1628	1631	001
O	1632	1634	at
O	1635	1638	mid
O	1638	1639	-
O	1639	1648	treatment
O	1649	1651	or
O	1652	1654	at
O	1655	1658	the
O	1659	1662	end
O	1663	1665	of
O	1666	1675	treatment
O	1675	1676	)
O	1676	1677	.

B-outcome	1678	1680	CR
I-outcome	1680	1681	-
I-outcome	1681	1685	SAEs
O	1686	1688	in
O	1689	1697	patients
O	1698	1702	with
O	1703	1706	EBC
O	1707	1710	are
O	1711	1719	frequent
O	1720	1723	but
O	1724	1730	rarely
O	1731	1737	impact
O	1738	1741	the
O	1742	1745	ACT
O	1746	1753	process
O	1753	1754	.

O	1755	1763	Compared
O	1764	1768	with
O	1769	1774	PORTs
O	1774	1775	,
O	1776	1781	PICCs
O	1782	1785	are
O	1786	1796	associated
O	1797	1801	with
O	1802	1803	a
O	1804	1817	significantly
O	1818	1824	higher
O	1825	1829	risk
O	1830	1832	of
O	1833	1835	CR
O	1835	1836	-
O	1836	1840	SAEs
O	1841	1844	and
O	1845	1849	more
O	1850	1860	discomfort
O	1860	1861	.

O	1862	1867	PORTs
O	1868	1874	should
O	1875	1877	be
O	1878	1887	preferred
O	1888	1891	for
O	1892	1895	ACT
O	1896	1910	administration
O	1911	1913	in
O	1914	1922	patients
O	1923	1927	with
O	1928	1931	EBC
O	1931	1932	.
